NZ789871A - FcRn antibodies and methods of use thereof - Google Patents
FcRn antibodies and methods of use thereofInfo
- Publication number
- NZ789871A NZ789871A NZ789871A NZ78987117A NZ789871A NZ 789871 A NZ789871 A NZ 789871A NZ 789871 A NZ789871 A NZ 789871A NZ 78987117 A NZ78987117 A NZ 78987117A NZ 789871 A NZ789871 A NZ 789871A
- Authority
- NZ
- New Zealand
- Prior art keywords
- cdr
- seq
- sequence
- subject
- lupus
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Physical Education & Sports Medicine (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662368803P | 2016-07-29 | 2016-07-29 | |
| US201662368770P | 2016-07-29 | 2016-07-29 | |
| NZ750462A NZ750462B2 (en) | 2017-07-31 | Fcrn antibodies and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ789871A true NZ789871A (en) | 2026-01-30 |
Family
ID=61016731
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ789871A NZ789871A (en) | 2016-07-29 | 2017-07-31 | FcRn antibodies and methods of use thereof |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US11345751B2 (https=) |
| EP (2) | EP3491025B1 (https=) |
| JP (3) | JP7094941B2 (https=) |
| KR (3) | KR102505995B1 (https=) |
| CN (2) | CN109790221B (https=) |
| AU (1) | AU2017301915B2 (https=) |
| BR (1) | BR112019001806A2 (https=) |
| CA (1) | CA3032415A1 (https=) |
| DK (1) | DK3491025T3 (https=) |
| ES (1) | ES2968439T3 (https=) |
| FI (1) | FI3491025T3 (https=) |
| HR (1) | HRP20240048T1 (https=) |
| HU (1) | HUE065780T2 (https=) |
| IL (3) | IL320058A (https=) |
| LT (1) | LT3491025T (https=) |
| NZ (1) | NZ789871A (https=) |
| PL (1) | PL3491025T3 (https=) |
| PT (1) | PT3491025T (https=) |
| RS (1) | RS65070B1 (https=) |
| SG (1) | SG11201900813RA (https=) |
| SI (1) | SI3491025T1 (https=) |
| SM (1) | SMT202400004T1 (https=) |
| WO (1) | WO2018023136A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS64768B1 (sr) * | 2015-01-30 | 2023-11-30 | Momenta Pharmaceuticals Inc | Fcrn antitela i načini njihove upotrebe |
| SMT202400004T1 (it) * | 2016-07-29 | 2024-03-13 | Momenta Pharmaceuticals Inc | Anticorpi fcrn e loro metodi di utilizzo |
| SG10202112298TA (en) * | 2017-05-11 | 2021-12-30 | Nat Univ Singapore | Targeted prevention of maternal to foetal vertical transmission of infection |
| CA3081144A1 (en) | 2017-12-08 | 2019-06-13 | Argenx Bvba | Use of fcrn antagonists for treatment of generalized myasthenia gravis |
| KR102904658B1 (ko) * | 2017-12-13 | 2025-12-29 | 모멘타 파머슈티컬스 인코포레이티드 | FcRn 항체 및 이의 사용 방법 |
| US12054558B2 (en) | 2018-05-23 | 2024-08-06 | The Jackson Laboratory | Anti-NGly-1 antibodies and methods of use |
| US12202900B2 (en) | 2018-06-08 | 2025-01-21 | argenx BV | Compositions and methods for treating immune thrombocytopenia |
| WO2020023310A1 (en) * | 2018-07-20 | 2020-01-30 | Williams Eva | Compositions of fcrn antibodies and methods of use thereof |
| CN113518783A (zh) * | 2018-07-20 | 2021-10-19 | 动量制药公司 | FcRn抗体组合物 |
| EP3969125A4 (en) * | 2019-05-17 | 2023-01-11 | Alexion Pharmaceuticals, Inc. | USE OF ANTI-FCRN ANTIBODIES IN THE TREATMENT OF PEMPHIGHUS AND PEMPHIGOID DISEASES |
| EP4007605A4 (en) * | 2019-08-01 | 2023-08-16 | Momenta Pharmaceuticals, Inc. | ANTI-FCRN ANTIBODIES AND METHODS OF USE THEREOF |
| AU2020387399A1 (en) * | 2019-11-19 | 2022-05-19 | Immunovant Sciences Gmbh | Methods of treating warm autoimmune hemolytic anemia using anti-FcRn antibodies |
| JP2023509195A (ja) | 2020-01-08 | 2023-03-07 | アルジェニクス ビーブイ | 天疱瘡症を治療する方法 |
| CN116234827A (zh) * | 2021-09-03 | 2023-06-06 | 舒泰神（北京）生物制药股份有限公司 | 特异性识别FcRn的抗体及其应用 |
| CN113912730B (zh) * | 2021-12-14 | 2022-03-04 | 北京科诺信诚科技有限公司 | 缓释的抗FcRn抗体或抗原结合片段及其应用 |
| CN119698429A (zh) | 2022-06-15 | 2025-03-25 | 阿根思有限公司 | Fcrn结合分子及使用方法 |
| AR131560A1 (es) * | 2023-01-06 | 2025-04-09 | argenx BV | Métodos para tratar pots mediante el uso de antagonistas de fcrn |
| USD1123829S1 (en) * | 2023-10-10 | 2026-04-28 | Shenzhen WETON Technology Co., Ltd. | Rechargeable card holder |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2534973A1 (en) | 2003-08-08 | 2005-02-17 | The Research Foundation Of State University Of New York | Anti-fcrn antibodies for treatment of auto/allo immune conditions |
| CN101124245A (zh) | 2003-11-12 | 2008-02-13 | 比奥根艾迪克Ma公司 | 新生儿Fc受体(FcRn)-结合多肽变体、二聚体Fc结合蛋白及其相关方法 |
| CA2637929A1 (en) | 2006-01-25 | 2007-08-02 | The Research Foundation Of State University Of New York | Anti-fcrn antibodies for treatement of auto/allo immune conditions |
| US20110059101A9 (en) | 2006-03-13 | 2011-03-10 | Ablynx N.V. | Amino Acid Sequences Directed Against Il-6 And Polypetides Comprising The Same For The Treatment Of Diseases And Disorders Associated With Il-6 Mediated Signalling |
| WO2009131702A2 (en) | 2008-04-25 | 2009-10-29 | Dyax Corp. | Antibodies against fcrn and use thereof |
| CN102549016B (zh) | 2009-06-30 | 2015-05-06 | 研究发展基金会 | 免疫球蛋白fc多肽 |
| AU2012262007B2 (en) * | 2011-06-02 | 2017-06-22 | Takeda Pharmaceutical Company Limited | Fc receptor binding proteins |
| GB201208370D0 (en) * | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Antibodies |
| ES2802274T3 (es) | 2013-05-02 | 2021-01-18 | Momenta Pharmaceuticals Inc | Glicoproteínas sialiladas |
| KR101815265B1 (ko) * | 2013-06-20 | 2018-01-04 | 한올바이오파마주식회사 | FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물 |
| PL3137504T3 (pl) * | 2014-04-30 | 2023-10-16 | Hanall Biopharma Co., Ltd. | Przeciwciało wiążące się z FcRn do leczenia chorób autoimmunologicznych |
| RS64768B1 (sr) | 2015-01-30 | 2023-11-30 | Momenta Pharmaceuticals Inc | Fcrn antitela i načini njihove upotrebe |
| EP3294335B1 (en) | 2015-05-12 | 2023-07-05 | Syntimmune Inc. | Humanized affinity matured anti-fcrn antibodies |
| SMT202400004T1 (it) * | 2016-07-29 | 2024-03-13 | Momenta Pharmaceuticals Inc | Anticorpi fcrn e loro metodi di utilizzo |
-
2017
- 2017-07-31 SM SM20240004T patent/SMT202400004T1/it unknown
- 2017-07-31 KR KR1020197006049A patent/KR102505995B1/ko active Active
- 2017-07-31 JP JP2019504902A patent/JP7094941B2/ja active Active
- 2017-07-31 RS RS20240046A patent/RS65070B1/sr unknown
- 2017-07-31 KR KR1020247033727A patent/KR20240151878A/ko active Pending
- 2017-07-31 DK DK17835436.1T patent/DK3491025T3/da active
- 2017-07-31 HU HUE17835436A patent/HUE065780T2/hu unknown
- 2017-07-31 HR HRP20240048TT patent/HRP20240048T1/hr unknown
- 2017-07-31 IL IL320058A patent/IL320058A/en unknown
- 2017-07-31 IL IL302288A patent/IL302288B2/en unknown
- 2017-07-31 SI SI201731447T patent/SI3491025T1/sl unknown
- 2017-07-31 KR KR1020237006882A patent/KR102717601B1/ko active Active
- 2017-07-31 AU AU2017301915A patent/AU2017301915B2/en active Active
- 2017-07-31 SG SG11201900813RA patent/SG11201900813RA/en unknown
- 2017-07-31 PT PT178354361T patent/PT3491025T/pt unknown
- 2017-07-31 ES ES17835436T patent/ES2968439T3/es active Active
- 2017-07-31 PL PL17835436.1T patent/PL3491025T3/pl unknown
- 2017-07-31 CN CN201780060620.6A patent/CN109790221B/zh active Active
- 2017-07-31 EP EP17835436.1A patent/EP3491025B1/en active Active
- 2017-07-31 NZ NZ789871A patent/NZ789871A/en unknown
- 2017-07-31 EP EP23195791.1A patent/EP4282487A3/en active Pending
- 2017-07-31 FI FIEP17835436.1T patent/FI3491025T3/fi active
- 2017-07-31 US US16/321,801 patent/US11345751B2/en active Active
- 2017-07-31 CA CA3032415A patent/CA3032415A1/en active Pending
- 2017-07-31 IL IL264528A patent/IL264528B2/en unknown
- 2017-07-31 WO PCT/US2017/044765 patent/WO2018023136A1/en not_active Ceased
- 2017-07-31 BR BR112019001806-9A patent/BR112019001806A2/pt active Search and Examination
- 2017-07-31 CN CN202311567291.8A patent/CN117679506A/zh active Pending
- 2017-07-31 LT LTEPPCT/US2017/044765T patent/LT3491025T/lt unknown
-
2022
- 2022-04-28 US US17/661,070 patent/US20230049725A1/en active Pending
- 2022-06-22 JP JP2022100315A patent/JP7442575B2/ja active Active
-
2024
- 2024-02-20 JP JP2024023875A patent/JP2024059765A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ789871A (en) | FcRn antibodies and methods of use thereof | |
| AU2018386193A8 (en) | FcRn antibodies and methods of use thereof | |
| TWI741987B (zh) | 特異性針對過度磷酸化τ蛋白之抗體及其使用方法 | |
| RU2425841C2 (ru) | Получение и анализ полностью человеческих лечебных антител-производных hucal gold, специфичных к человеческому cd38 | |
| JOP20190248A1 (ar) | بروتينات ربط مولد ضد trem2 واستخداماته | |
| EA202092933A1 (ru) | Антитела к entpd2, виды комбинированной терапии и способы применения антител и видов комбинированной терапии | |
| PH12021552334A1 (en) | Antibodies to pyroglutamate amyloid-ã and uses thereof | |
| WO2020139175A3 (ru) | Моноклональные антитела против участка бета-цепи trbv9 человека | |
| JP2017536111A5 (https=) | ||
| HRP20220918T1 (hr) | Anti-transtiretinska antitijela | |
| FI3332006T3 (fi) | Uusia anti-PD-L1-vasta-aineita | |
| JP2018500924A5 (https=) | ||
| PH12023551241A1 (en) | Fcrn antibodies and methods of use thereof | |
| JP2015508072A5 (https=) | ||
| PH12021551535A1 (en) | Monoclonal antibodies that bind specifically to human trbv9 | |
| MA37670B1 (fr) | Anticorps anti-transglutaminase 2 | |
| JP7645544B2 (ja) | Ｉｌ－１ｒ１およびｎｌｐｒ３標的化二重特異性抗体 | |
| EA202192907A1 (ru) | Моноклональное антитело, которое специфически связывается с gitr | |
| CN118647405A (zh) | 改善认知障碍的方法 | |
| US20250163149A1 (en) | Anti-rage antibody | |
| TWI816621B (zh) | 抗體及其應用 | |
| MA44917A1 (fr) | Anticorps ou son fragment de liaison d’antigènes apte a se lier au récepteur d'interleukine-6 de l'humain. | |
| WO2023147489A3 (en) | Anti-musk antibodies for use in treating neuromuscular disorders | |
| JP2019531254A5 (https=) | ||
| Woehrer et al. | Clinical Neuropathology image 1-2015: Crystal-storing histiocytosis of the central nervous system |